In particular, due to the excellent efficacy results of RET-TKIs, they were quickly approved for indications in just 2 years and became the first-line treatment recommendation for patients with RET-fusion-positive NSCLC in the National Comprehensive Cancer Network guidelines. The gene discussed is RET; the disease is non-small cell lung carcinoma.